Analysts Set Expectations for Edwards Lifesciences Co.’s Q1 2025 Earnings (NYSE:EW)

Edwards Lifesciences Co. (NYSE:EWFree Report) – Stock analysts at William Blair issued their Q1 2025 EPS estimates for shares of Edwards Lifesciences in a note issued to investors on Tuesday, June 4th. William Blair analyst M. Kaczor anticipates that the medical research company will post earnings per share of $0.76 for the quarter. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.77 per share. William Blair also issued estimates for Edwards Lifesciences’ Q2 2025 earnings at $0.79 EPS, Q3 2025 earnings at $0.76 EPS and Q4 2025 earnings at $0.80 EPS.

Edwards Lifesciences (NYSE:EWGet Free Report) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion.

A number of other research firms have also issued reports on EW. Oppenheimer raised their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 18th. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Mizuho boosted their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. StockNews.com raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Monday, April 29th. Finally, Royal Bank of Canada upped their price target on Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a report on Monday, April 15th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.06.

Check Out Our Latest Stock Analysis on EW

Edwards Lifesciences Trading Up 0.7 %

Shares of EW stock opened at $87.68 on Friday. The business’s 50 day moving average is $88.50 and its two-hundred day moving average is $82.87. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08. Edwards Lifesciences has a 12 month low of $60.57 and a 12 month high of $96.12. The company has a market cap of $52.84 billion, a PE ratio of 37.79, a price-to-earnings-growth ratio of 3.19 and a beta of 1.11.

Insider Buying and Selling

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $94.89, for a total value of $688,426.95. Following the sale, the chief financial officer now directly owns 19,074 shares in the company, valued at $1,809,931.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $94.89, for a total value of $688,426.95. Following the transaction, the chief financial officer now directly owns 19,074 shares in the company, valued at $1,809,931.86. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $91.68, for a total value of $1,320,192.00. Following the sale, the vice president now owns 173,584 shares in the company, valued at $15,914,181.12. The disclosure for this sale can be found here. Insiders sold 151,004 shares of company stock worth $13,469,601 in the last 90 days. 1.29% of the stock is owned by company insiders.

Hedge Funds Weigh In On Edwards Lifesciences

A number of large investors have recently modified their holdings of EW. Crewe Advisors LLC bought a new position in Edwards Lifesciences in the first quarter valued at approximately $28,000. Riverview Trust Co acquired a new stake in shares of Edwards Lifesciences during the first quarter worth about $34,000. DSM Capital Partners LLC acquired a new stake in Edwards Lifesciences during the 4th quarter worth approximately $28,000. Turtle Creek Wealth Advisors LLC bought a new stake in Edwards Lifesciences in the 4th quarter valued at $34,000. Finally, Rise Advisors LLC boosted its position in shares of Edwards Lifesciences by 125.0% during the first quarter. Rise Advisors LLC now owns 477 shares of the medical research company’s stock worth $46,000 after buying an additional 265 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

About Edwards Lifesciences

(Get Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Further Reading

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.